While GIP alone has limited therapeutic use in T2DM due to impaired responsiveness, combining GIP agonism with GLP-1 activity produces synergistic metabolic effects in medications that have dual effects, such as tirzepatide. The gene discussed is GIP; the disease is type 2 diabetes mellitus.